Cellectar Biosciences, Inc. (CLRB) vs Neuphoria Therapeutics Inc. (NEUP)

Cellectar Biosciences, Inc. and Neuphoria Therapeutics Inc. are both Biotechnology companies. Cellectar Biosciences, Inc. and Neuphoria Therapeutics Inc. are of similar size ($19.8M and $19.6M). Across the 10 metrics below, Neuphoria Therapeutics Inc. leads on 7 and Cellectar Biosciences, Inc. on 3.

Valuation

Metric CLRB NEUP Biotechnology median
P/E n/m n/m 7.88
P/S n/m 1.02 11.47
P/B 0.74 0.65 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.50 0.17 0.74
EV/Sales n/m (0.19) 10.73
Earnings yield (213.33%) (138.08%) (28.84%)
Free cash flow yield (88.77%) (76.04%) (23.03%)

Profitability

Metric CLRB NEUP Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (125.99%) (61.70%) (57.72%)
Return on assets (88.70%) (46.95%) (49.22%)
Return on invested capital 0.00% (232.67%) 0.00%

Growth

Metric CLRB NEUP Biotechnology median
Revenue growth (TTM) — 3,535.05% 5.64%
EPS growth (last fiscal year) 80.14% (1,230.43%) —
Revenue growth, 5-year CAGR — 19.07% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLRB NEUP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.66 27.85 4.73
Net debt to EBITDA 0.58 1.26 0.96

Dividend

Metric CLRB NEUP Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLRB NEUP Biotechnology median
Market cap 19.61m 19.75m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack